UCI Investigates Synthetic Vasoactive Intestinal Polypeptide-based Experimental Drug on High Risk SARS-CoV-2 Patients

UCI Investigates Synthetic Vasoactive Intestinal Polypeptide-based Experimental Drug on High Risk SARS-CoV-2 Patients

University of California Irvine, (UCI) recently announced their participation in a COVID-19-focused clinical trial investigating a drug called Aviptadil in at risk patients. Dr. Richard Lee, Interim chief of UCK Health Division of Pulmonary Diseases and Critical Care...

Pin It on Pinterest